ClinicalTrials.gg
RecruitingNCT03836482NEUTRALIZE-CRSUpdated Mar 31, 2026

Feasibility of the SCD in Cardiorenal Syndrome Patients Awaiting LVAD

An interventional study of Selective Cytopheretic Device in Acute on Chronic Systolic Congestive Heart Failure and Cardiorenal Syndrome, sponsored by SeaStar Medical. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-31.

Sponsored by SeaStar Medical · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Cardio-Renal Syndrome with a site in United States — 3 open to participants now, 3 under way, none of them phase 3. Cardio-Renal Syndrome · United States.

Planned enrollment
8th of 16
20 · median 20
Started
2025
with 1 other
No phase
6 of 18
3 open now
Registered
12th of 18
by date

Among the 18 studies in Cardio-Renal Syndrome with a site in United States, this one is the 8th largest by planned enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2025, is one of 6 with no phase, and was the 12th registered.

Cardio-Renal Syndrome

85 studies on the registry are indexed under Cardio-Renal Syndrome; 20 are open to participants now.

Browse Cardio-Renal Syndrome studies →

Open to participants now

3 of the 18 studies in Cardio-Renal Syndrome with a site in United States are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 12 Cardio-Renal Syndrome studies recruiting now, 9 (75%) set no upper age limit and 2 (17%) stop at 75 or younger; 2 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Cardio-Renal Syndrome with a site in United States, or all of them as a file.
02

Study summary

Cardiovascular disease is the leading cause of mortality in the US, accounting for 45% of all deaths. Chronic Heart Failure (CHF) is now understood to be a multi-system disease process involving not only the cardiovascular system but also the renal, neuroendocrine, and immune systems. No effective therapy is currently available to treat the most severe subset of CHF patients that have progressed to acute decompensated HF. An innovative approach to reduce the cardio-depressant effects associated with the chronic inflammatory state of CHF may provide a breakthrough for this disorder. This proposal will evaluate the safety and probable benefit to improve cardiac or renal function with an immunomodulatory device to bridge patients to Left Ventricular Assist Device (LVAD) implantation who were previously deemed ineligible for this life sustaining procedure. The Selective Cytopheretic Device (SCD) is an immuno-regulating, extracorporeal membrane device targeted to modulate the cardiodepressant effects assocaited with CHF. SCD is a platform technology focused on immunomodulation of acute and chronic inflammation associated with acute and chronic organ dysfunction. SCD membranes selectively sequester activated systemic leukocytes as they flow through the cartridge via an extracorporeal circuit. Pre-clinical results show that SCD treatment results in a 25% improvement in ejection fraction in a canine CHF model.

This study will enroll 20 patients across up to 5 clinical sites to evaluate the safety and initial efficacy data of SCD treatment in this indication. Patients will receive 4-hour daily SCD treatment for up to 6 days, followed by 6 months of follow up.

03

Conditions studied

  • Acute on Chronic Systolic Congestive Heart Failure
  • Cardiorenal Syndrome

Browse trials for

Keywords

  • Awaiting Left ventricular assist device implantation
  • Hospitalized
  • Selective Cytopheretic Device
  • SCD
  • LVAD
  • CRS
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age of 18 years and older.
  2. Evidence of systemic inflammation: blood CRP ≥ 4.5 mg/L or IL-6 ≥ 5.0 pg/ml or neutrophil to lymphocyte ratio ≥3.0.
  3. Primary hospitalization for acute decompensated chronic systolic heart failure.
  4. Potential LVAD candidate with:

    a) ≤25% (for potential destination therapy) or ≤ 35% (for potential bridge to transplantation) as confirmed by baseline imaging procedure b) class IIIB or IV chronic (≤ 90 days) systolic heart failure, with failure to respond to optimal medical therapy (beta blocker, ACE inhibitor or ARB or valsartan/sacubitril, aldosterone antagonist, SGLT2i, unless not tolerated or , and loop diuretic, as needed) for 45 of the last 60 days c) Known previous peak exercise oxygen consumption \< 14 mL/Kg/min or if unable to exercise, dependent on an intra-aortic balloon pump, short-term mechanical circulatory support device or intravenous inotropes unless inotropes contraindicated for clinical reasons (e.g., ventricular arrhythmias)

  5. Baseline ** ≥ 40 ml/min/1.73 m2 (baseline defined as the highest known eGFR within 90 days of study enrollment)
  6. At least one of the following two criteria:

    1. Severe right ventricular failure (RVF), defined as meeting at least 2 of the following 4 criteria -Central venous pressure > 16 mmHg

      -Central venous pressure/Pulmonary wedge pressure >0.65

      -Right ventricular stroke work index \< 300 mmHg * ml/m2

      -Pulmonary artery pulsatility index (PAPi) \< 2,

    2. Worsening renal failure (WRF), defined for the purposes of this study as -Increase serum creatinine ≥ 0.5 mg/dL from baseline (baseline defined as the lowest known serum creatinine within 90 days of study enrollment) AND

      • eGFR** ≤ 30 ml/min/1.73 m2 based on serum creatinine at enrollment*** AND
      • Cardiorenal syndrome is the most likely explanation for WRF AND
      • Intolerant or inadequately responsive to standard of care diuretic therapy, defined as persistent signs and/or symptoms of congestion (e.g., peripheral edema, dyspnea, pulmonary rales, neck vein distension) or minimal net volume removal in a 24-hour period despite optimal medical therapy including intravenous diuretic therapy and an estimated need for >5kg fluid removal.

        1. Optimal intravenous diuretic therapy is defined as:

          1. Furosemide equivalent total daily dose of 240mg
          2. Furosemide equivalent dose given either as a single or multiple intravenous bolus or continuous infusion
          3. A furosemide equivalent total daily dose \<240mg if the dose has resulted in >3000 mL urine output/24 hours.
  7. PA catheter in place at the time of enrollment
  8. PCW ≥ 20 mmHg

    • eGFR calculated using the CKD-EPI Creatinine Equation *** Recognizing that this is not a steady state creatinine

Exclusion criteria

Exclusion Criteria:

  1. Any clear to LVAD therapy that is unlikely to resolve with improvement in renal function and volume status
  2. Prior sensitivity to dialysis device components
  3. Active bacteremia
  4. Temperature ≥ 101.5 F or WBC ≥ 10,000 K/uL or any patient with suspected systemic infection.
  5. requiring palliative chemo, biologic, or radiation
  6. Need for intravenous vasopressor (i.e., phenylephrine, vasopressin), intravenous vasoconstricting inotrope (i.e., norepinephrine or epinephrine) or dopamine > 3 mcg/kg/min. (Note: use of vasodilating inotropes [i.e., dobutamine and milrinone] or dopamine at ≤ 3 mcg/kg/min will not preclude study inclusion)
  7. Patients requiring mechanical ventilatory support
  8. Patients requiring total parenteral nutrition during the treatment period
  9. Persistent SBP \< 80 mmHg
  10. WBC \< 4000 K/uL
  11. \< 100,000K/uL
  12. Serum creatinine > 4 mg/dL or receiving dialysis / CRRT
  13. Acute coronary syndrome within the past month
  14. Women who are pregnant, breastfeeding a child, or trying to become pregnant
  15. Concurrent enrollment in another interventional clinical trial. Patients enrolled in clinical studies where only measurements and/or samples are taken (i.e., no test device or test drug used) are allowed to participate
  16. Use of any other drug or device within the previous 30 days. Patients who participated in a clinical study where only measurements and/or samples are taken (i.e., no test device or drug used) are allowed to participate.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Selective Cytopheretic Device

    Device: Selective Cytopheretic Device

Interventions

  • DeviceSelective Cytopheretic Device

    Treatment will be delivered for 4 hours a day for up to 6 consecutive days.

06

What researchers measure

Primary outcomes

  1. Need for continuous IV vasopressor support

    Need for continuous IV vasopressor support with \>5 total norepinephrine equivalents and/or \>3 vasopressor agents \>4 hours following termination of daily SCD therapy session to maintain a MAP \>60 mmHg, with norepinephrine equivalents defined as: 1. 1 x epinephrine (ug/kg/min) 2. 001 x dopamine (ug/kg/min) 3. 0.06 x phenylephrine (ug/kg/min) 4. 2.5 x vasopressin (U/min) (Note that use of inotropes (i.e., dobutamine and milrinone) or dopamine at ≤3 mcg/kg/min are not components of this measure.)

    Time frame: measured daily, at or after 4 hours after termination of daily SCD therapy

  2. Acute myocardial infarction

    Acute myocardial infarction as evidenced by elevated cardiac enzymes, with electrocardiographic or imaging findings consistent with myocardial damage and confirmed by Cardiology.

    Time frame: up to 6 months following SCD treatment initiation

  3. Mortality

    Death

    Time frame: up to 6 months following SCD treatment initiation

  4. Percentage of subjects with reversal of WRF and increase eGFR and PCW

    Among patients with WRF, the percentage of subjects with reversal of WRF (≥ 0.5 mg/dL reduction of serum creatinine from level at study entry), and achieving an eGFR \> 30 ml/min/1.73 m2 and PCWP at or below level at study entry at termination of SCD therapy.

    Time frame: up to 6 days after initiation of SCD therapy

  5. Percentage of subjects who no longer have severe right ventricular failure

    Among subjects with severe RVF, the percentage of subjects who no longer have severe right ventricular failure, as evidenced by absence of 3 or more of the following 4 indicators of right ventricular failure: 1. CVP \> 16 mmHg 2. CVP/PCWP \> 0.65 3. RVSWI \< 300 mmHg \* mL/m 4. PAPi \< 2

    Time frame: up to 6 days after initiation of SCD therapy

  6. Adverse Events

    Adverse Events due to SCD, hemodialysis catheter, KRT pump, circuit, and hemofilter

    Time frame: up to 6 days after initiation of SCD therapy

Secondary outcomes

  1. Percentage of subject receiving a left ventricular assist device

    Time frame: up to 30 days after the last SCD

  2. Change in 24 hour urine volume

    Time frame: change from onset of intervention to 3 and 6 days after initiation of SCD treatments and from onset of intervention to end of SCD support prior to LVAD implantation

  3. Change in urine sodium

    Time frame: change from onset of intervention to 3 and 6 days after initiation of SCD treatments and from onset of intervention to end of SCD support prior to LVAD implantation

  4. Change in urine creatinine

    Time frame: change from onset of intervention to 3 and 6 days after initiation of SCD treatments and from onset of intervention to end of SCD support prior to LVAD implantation

  5. Change in urine urea

    Time frame: change from onset of intervention to 3 and 6 days after initiation of SCD treatments and from onset of intervention to end of SCD support prior to LVAD implantation

  6. Change in creatinine clearance

    Time frame: change from onset of intervention to 3 and 6 days after initiation of SCD treatments and from onset of intervention to end of SCD support prior to LVAD implantation

  7. Change in urine urea clearance

    Time frame: change from onset of intervention to 3 and 6 days after initiation of SCD treatments and from onset of intervention to end of SCD support prior to LVAD implantation

  8. Change in Pulmonary Capillary Wedge Pressure (PCWP)

    If PCWP cannot be obtained, Pulmonary Artery Diastolic Pressure (PADP) will be used in its place. When utilizing PADP in place of PCWP for change measures, comparisons will be made to baseline PADP.

    Time frame: change from onset of intervention to 3 and 6 days after initiation of SCD treatments and from onset of intervention to end of SCD support prior to LVAD implantation

  9. Change in serum sodium

    Time frame: change from onset of intervention to 3 and 6 days after initiation of SCD treatments and from onset of intervention to end of SCD support prior to LVAD implantation

  10. Change in serum potassium

    Time frame: change from onset of intervention to 3 and 6 days after initiation of SCD treatments and from onset of intervention to end of SCD support prior to LVAD implantation

  11. Change in serum dissolved carbon dioxide (CO2)

    Time frame: change from onset of intervention to 3 and 6 days after initiation of SCD treatments and from onset of intervention to end of SCD support prior to LVAD implantation

  12. Change in blood urea nitrogen (BUN)

    Time frame: change from onset of intervention to 3 and 6 days after initiation of SCD treatments and from onset of intervention to end of SCD support prior to LVAD implantation

  13. Change in serum creatinine

    Time frame: change from onset of intervention to 3 and 6 days after initiation of SCD treatments and from onset of intervention to end of SCD support prior to LVAD implantation

  14. Percentage of subjects with reduction of serum creatinine (≥ 0.5 mg/dL) and PCWP (≤ 18 mmHg)

    If PCWP cannot be obtained, PADP will be used in its place. When utilizing PADP in place of PCWP for change measures, comparisons will be made to baseline PADP

    Time frame: change from onset of intervention to 3 and 6 days after initiation of SCD treatments and from onset of intervention to end of SCD support prior to LVAD implantation

  15. Percentage of subjects receiving a left ventricular assist device with serum creatinine ≥ 0.5 mg/dL below level at study entry

    Time frame: 30 days following discontinuation of SCD

  16. Change in right ventricular fractional area change

    Change in right ventricular fractional area change, TAPSE, and right ventricular global longitudinal strain

    Time frame: change from onset of intervention to 3 and 6 days after initiation of SCD treatments and from onset of intervention to end of SCD support prior to LVAD implantation

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2025 (actual). Primary completion is estimated for Feb 2027, 16 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 7, 2019
First posted
Feb 11, 2019
StartActual
Oct 2, 2025
Primary completionEst.
Feb 2027
CompletionEst.
Aug 2027
Last update
Mar 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03836482
Lead sponsor
SeaStar Medical
Responsible party
Sponsor
First posted
Feb 11, 2019
Start date
Oct 2, 2025
Primary completion
Feb 2027 (estimated)
Completion
Aug 2027 (estimated)
Last update
Mar 31, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion